There are some other rare mutations in NSCLC patients, such as HER2 exon 20 in-frame insertions/amplification, FGFR1 amplification, FGFR2–4 mutation, NGR1 gene fusion/translocation/mutation, and the PI3K pathway, including pTEN protein loss, PI3K amplification and mutation, and pTEN R233* and AKT1 mutation. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.